Feasibly of CD24/CD11b as a Screening Test for Hematological Malignancies

Feasibly of CD24/CD11b as a Screening Test for Hematological Malignancies

An estimated 1.24 million blood cancer cases occur annually worldwide, accounting for approximately 6% of all cancer cases. Currently, there are no standardized hematology cancer screening tests that are recommended for the general population. CD24 is a mucin-like cell surface molecule and P-selecti...

Full description

Bibliographic Details
Main Authors: Shiran Shapira, Dina Kazanov, Fatin Mdah, Hadas Yaakobi, Yair Herishanu, Chava Perry, Irit Avivi, Gilad Itchaki, Adi Shacham-Abulafia, Pia Raanani, Mori Hay-Levy, Gal Aiger, Jacob Mashiah, Shahar Lev-Ari, Nadir Arber
Format: Article
Language:English
Published: MDPI AG 2021-07-01
Series:Journal of Personalized Medicine
Subjects:
CD24
hematologic cancer
prevention
screening test
sensitivity
specificity
Online Access:https://www.mdpi.com/2075-4426/11/8/724

Internet

https://www.mdpi.com/2075-4426/11/8/724

Similar Items